Immunic (NASDAQ:IMUX) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Immunic (NASDAQ:IMUX) in a research note published on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $10.00 target price on the stock.

Other analysts also recently issued reports about the stock. Leerink Partners reiterated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. B. Riley initiated coverage on Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective for the company. Leerink Partnrs raised Immunic to a “strong-buy” rating in a report on Monday, September 9th. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a report on Monday, September 16th. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $11.80.

Immunic Price Performance

Shares of IMUX opened at $1.18 on Monday. Immunic has a 12-month low of $0.97 and a 12-month high of $2.11. The business’s fifty day moving average price is $1.39 and its 200 day moving average price is $1.34. The stock has a market capitalization of $106.29 million, a PE ratio of -0.96 and a beta of 1.88.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick purchased 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now owns 87,300 shares in the company, valued at $100,395. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunic

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Immunic in the third quarter worth approximately $50,000. Jane Street Group LLC grew its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. State Street Corp grew its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Ikarian Capital LLC grew its position in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.